Ignite Creation Date:
2024-05-05 @ 9:17 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00853827
Status:
COMPLETED
Last Update Posted:
2014-06-03
First Post:
2009-02-26
Brief Title:
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 104 Week Randomized Double Blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AQUARIUS
Brief Summary:
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound IVUS for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery disease CAD and a blood pressure in the pre-hypertensive range
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-006447-40 | None | None | None |